Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31318108 | 1.00 | TSHR (0.38) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL7155138 | 1.00 | TSHR (0.38) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL10524053 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL15350859 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL15351783 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL15350980 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL5265569 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL9442715 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL380862 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB | |
| SCHEMBL15351768 | 0.98 | TSHR (0.37) | TSHRLPAR1LPAR3LPAR2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943067-B2 | A polymerized hydrogel particles are first encapsulated the hydrogel-forming components into liposomes; drug delivery, drug targeting, protein separation, enzyme immobilization | POLYTECHNIC INSTITUTE OF NEW YORK UNIVERSITY (US) | 2011-05-17 | — | — | US | claimed |
| EP-1425112-B1 | Method of manufacturing hydrogel particles of nano size | UNIV POLYTECHNIC (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1425112-A4 | NANOGELS AND THEIR PRODUCTION USING LIPOSOMES AS REACTORS | UNIV POLYTECHNIC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040203091-A1 | Process for synthesizing protein using cell-free protein synthesis system | RIKEN (JP) | 2004-10-14 | — | — | US | claimed |
| EP-1425112-A1 | NANOGELS AND THEIR PRODUCTION USING LIPOSOMES AS REACTORS | POLYTECHNIC UNIVERSITY (US) | 2004-06-09 | — | — | EP | claimed |
| EP-1384778-A1 | PROCESS FOR SYNTHESIZING PROTEIN USING CELL-FREE PROTEIN SYNTHESIS SYSTEM | RIKEN (JP) | 2004-01-28 | — | — | EP | claimed |
| US-20030044455-A1 | Nanogels and their production using liposomes as reactors | POLYTECHNIC INSTITUTE OF NEW YORK UNIVERSITY | 2003-03-06 | — | — | US | claimed |
| WO-2003015936-A1 | NANOGELS AND THEIR PRODUCTION USING LIPOSOMES AS REACTORS | POLYTECHNIC UNIVERSITY (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2025122719-A1 | DIALYSIS-BASED METHOD FOR AFFINITY MAPPING OF CHROMATIN INTERACTIONS | CZ BIOHUB SF, LLC (US) | 2025-06-12 | — | — | WO | disclosed |
| US-11618777-B2 | Method of manufacturing membrane protein and utilization thereof | Yokoyama, Shigeyuki (JP) | 2023-04-04 | — | — | US | disclosed |
| US-20210055188-A1 | METHODS FOR ISOLATING, DETECTING, AND/OR ANALYZING ANTIBODIES FROM A FORMALIN FIXED PARAFFIN EMBEDDED (FFPE) TISSUE SAMPLE | SHIMADZU CORPORATION (JP) | 2021-02-25 | — | — | US | disclosed |
| US-20190194286-A1 | METHOD OF MANUFACTURING MEMBRANE PROTEIN AND UTILIZATION THEREOF | YOKOYAMA, SHIGEYUKI (JP) | 2019-06-27 | — | — | US | disclosed |
| EP-2841040-B1 | ABSORBENT ARTICLE COMPRISING WATER-ABSORBENT RESIN POWDER | LIVEDO CORP (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2841040-A1 | ABSORBENT ARTICLE COMPRISING WATER-ABSORBENT RESIN POWDER | Livedo Corporation (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20030044455-A1 | Nanogels and their production using liposomes as reactors | POLYTECHNIC INSTITUTE OF NEW YORK UNIVERSITY | 2003-03-06 | — | — | US | disclosed |
| WO-2003015936-A1 | NANOGELS AND THEIR PRODUCTION USING LIPOSOMES AS REACTORS | POLYTECHNIC UNIVERSITY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-5952312-A | TOPICALLY APPLYING NADH OR NADPH, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, TO THE SKIN OF A PERSON TO STIMULATE ATP PRODUCTION OF THE SKIN CELLS, WHEREIN THE NADH OR NADPH OR SALT IS STABILIZED AGAINST OXIDATION | BIRKMAYER PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5750512-A | FOR TREATMENT OF PARKINSON'S AND ALZHEIMER'S DISEASE OR MENTAL DEPRESSION | BIRKMAYER PHARMACEUTICALS, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5654288-A | OXIDATION RESISTANCE | BIRKMAYER PHARMACEUTICALS, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0722734-A1 | NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration | BIRKMAYER U.S.A. (US) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044455-A1 | Nanogels and their production using liposomes as reactors | PHOSPHO1, LIPA, PLD1 | TSHR 3957/4885LPAR1 99/4885LPAR3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.